Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 6
2004 4
2005 6
2006 11
2007 6
2008 10
2009 7
2010 6
2011 3
2012 6
2013 6
2014 10
2015 9
2016 7
2017 9
2018 5
2019 13
2020 18
2021 20
2022 11
2023 10
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

165 results

Results by year

Filters applied: . Clear all
Page 1
Cardiac metabolism as a driver and therapeutic target of myocardial infarction.
Zuurbier CJ, Bertrand L, Beauloye CR, Andreadou I, Ruiz-Meana M, Jespersen NR, Kula-Alwar D, Prag HA, Eric Botker H, Dambrova M, Montessuit C, Kaambre T, Liepinsh E, Brookes PS, Krieg T. Zuurbier CJ, et al. Among authors: andreadou i. J Cell Mol Med. 2020 Jun;24(11):5937-5954. doi: 10.1111/jcmm.15180. Epub 2020 May 8. J Cell Mol Med. 2020. PMID: 32384583 Free PMC article. Review.
Multitarget Strategies to Reduce Myocardial Ischemia/Reperfusion Injury: JACC Review Topic of the Week.
Davidson SM, Ferdinandy P, Andreadou I, Bøtker HE, Heusch G, Ibáñez B, Ovize M, Schulz R, Yellon DM, Hausenloy DJ, Garcia-Dorado D; CARDIOPROTECTION COST Action (CA16225). Davidson SM, et al. Among authors: andreadou i. J Am Coll Cardiol. 2019 Jan 8;73(1):89-99. doi: 10.1016/j.jacc.2018.09.086. J Am Coll Cardiol. 2019. PMID: 30621955 Free article. Review.
Interaction of Cardiovascular Nonmodifiable Risk Factors, Comorbidities and Comedications With Ischemia/Reperfusion Injury and Cardioprotection by Pharmacological Treatments and Ischemic Conditioning.
Ferdinandy P, Andreadou I, Baxter GF, Bøtker HE, Davidson SM, Dobrev D, Gersh BJ, Heusch G, Lecour S, Ruiz-Meana M, Zuurbier CJ, Hausenloy DJ, Schulz R. Ferdinandy P, et al. Among authors: andreadou i. Pharmacol Rev. 2023 Jan;75(1):159-216. doi: 10.1124/pharmrev.121.000348. Epub 2022 Dec 8. Pharmacol Rev. 2023. PMID: 36753049 Free PMC article. Review.
Shining the spotlight on cardioprotection: beyond the cardiomyocyte.
Davidson SM, Andreadou I, Garcia-Dorado D, Hausenloy DJ. Davidson SM, et al. Among authors: andreadou i. Cardiovasc Res. 2019 Jun 1;115(7):1115-1116. doi: 10.1093/cvr/cvz072. Cardiovasc Res. 2019. PMID: 30865272 Free PMC article. No abstract available.
Sodium Glucose Cotransporter-2 Inhibitor Empagliflozin Reduces Infarct Size Independently of Sodium Glucose Cotransporter-2.
Chen S, Wang Q, Christodoulou A, Mylonas N, Bakker D, Nederlof R, Hollmann MW, Weber NC, Coronel R, Wakker V, Christoffels VM, Andreadou I, Zuurbier CJ. Chen S, et al. Among authors: andreadou i. Circulation. 2023 Jan 17;147(3):276-279. doi: 10.1161/CIRCULATIONAHA.122.061688. Epub 2023 Jan 17. Circulation. 2023. PMID: 36649392 No abstract available.
Health position paper and redox perspectives on reactive oxygen species as signals and targets of cardioprotection.
Heusch G, Andreadou I, Bell R, Bertero E, Botker HE, Davidson SM, Downey J, Eaton P, Ferdinandy P, Gersh BJ, Giacca M, Hausenloy DJ, Ibanez B, Krieg T, Maack C, Schulz R, Sellke F, Shah AM, Thiele H, Yellon DM, Di Lisa F. Heusch G, et al. Among authors: andreadou i. Redox Biol. 2023 Nov;67:102894. doi: 10.1016/j.redox.2023.102894. Epub 2023 Oct 6. Redox Biol. 2023. PMID: 37839355 Free PMC article. Review.
Editorial: PCSK9: Importance in Physiology and Pathophysiology.
Schulz R, Andreadou I, Ferdinandy P. Schulz R, et al. Among authors: andreadou i. Front Physiol. 2021 Jul 26;12:706115. doi: 10.3389/fphys.2021.706115. eCollection 2021. Front Physiol. 2021. PMID: 34381377 Free PMC article. No abstract available.
Chronic inflammatory diseases, myocardial function and cardioprotection.
Lazou A, Ikonomidis I, Bartekova M, Benedek T, Makavos G, Palioura D, Cabrera Fuentes H, Andreadou I. Lazou A, et al. Among authors: andreadou i. Br J Pharmacol. 2020 Dec;177(23):5357-5374. doi: 10.1111/bph.14975. Epub 2020 Feb 8. Br J Pharmacol. 2020. PMID: 31943142 Free PMC article. Review.
Hyperlipidaemia and cardioprotection: Animal models for translational studies.
Andreadou I, Schulz R, Badimon L, Adameová A, Kleinbongard P, Lecour S, Nikolaou PE, Falcão-Pires I, Vilahur G, Woudberg N, Heusch G, Ferdinandy P. Andreadou I, et al. Br J Pharmacol. 2020 Dec;177(23):5287-5311. doi: 10.1111/bph.14931. Epub 2020 Jan 17. Br J Pharmacol. 2020. PMID: 31769007 Free PMC article. Review.
Heart failure pharmacotherapy and cancer: pathways and pre-clinical/clinical evidence.
Sayour NV, Paál ÁM, Ameri P, Meijers WC, Minotti G, Andreadou I, Lombardo A, Camilli M, Drexel H, Grove EL, Dan GA, Ivanescu A, Semb AG, Savarese G, Dobrev D, Crea F, Kaski JC, de Boer RA, Ferdinandy P, Varga ZV. Sayour NV, et al. Among authors: andreadou i. Eur Heart J. 2024 Apr 7;45(14):1224-1240. doi: 10.1093/eurheartj/ehae105. Eur Heart J. 2024. PMID: 38441940 Free PMC article. Review.
165 results